Literature DB >> 34534966

Bicentric validation of the navigated transcranial magnetic stimulation motor risk stratification model.

Tizian Rosenstock1,2, Levin Häni3, Ulrike Grittner4, Nicolas Schlinkmann1, Meltem Ivren1, Heike Schneider1, Andreas Raabe3, Peter Vajkoczy1, Kathleen Seidel3, Thomas Picht1,5.   

Abstract

OBJECTIVE: The authors sought to validate the navigated transcranial magnetic stimulation (nTMS)-based risk stratification model. The postoperative motor outcome in glioma surgery may be preoperatively predicted based on data derived by nTMS. The tumor-to-tract distance (TTD) and the interhemispheric resting motor threshold (RMT) ratio (as a surrogate parameter for cortical excitability) emerged as major factors related to a new postoperative deficit.
METHODS: In this bicentric study, a consecutive prospectively collected cohort underwent nTMS mapping with diffusion tensor imaging (DTI) fiber tracking of the corticospinal tract prior to surgery of motor eloquent gliomas. The authors analyzed whether the following items were associated with the patient's outcome: patient characteristics, TTD, RMT value, and diffusivity parameters (fractional anisotropy [FA] and apparent diffusion coefficient [ADC]). The authors assessed the validity of the published risk stratification model and derived a new model.
RESULTS: A new postoperative motor deficit occurred in 36 of 165 patients (22%), of whom 20 patients still had a deficit after 3 months (13%; n3 months = 152). nTMS-verified infiltration of the motor cortex as well as a TTD ≤ 8 mm were confirmed as risk factors. No new postoperative motor deficit occurred in patients with TTD > 8 mm. In contrast to the previous risk stratification, the RMT ratio was not substantially correlated with the motor outcome, but high RMT values of both the tumorous and healthy hemisphere were associated with worse motor outcome. The FA value was negatively associated with worsening of motor outcome. Accuracy analysis of the final model showed a high negative predictive value (NPV), so the preoperative application may accurately predict the preservation of motor function in particular (day of discharge: sensitivity 47.2%, specificity 90.7%, positive predictive value [PPV] 58.6%, NPV 86.0%; 3 months: sensitivity 85.0%, specificity 78.8%, PPV 37.8%, NPV 97.2%).
CONCLUSIONS: This bicentric validation analysis further improved the model by adding the FA value of the corticospinal tract, demonstrating the relevance of nTMS/nTMS-based DTI fiber tracking for clinical decision making.

Entities:  

Keywords:  apparent diffusion coefficient; brain tumor surgery; diagnostic technique; diffusion tensor imaging; fractional anisotropy; glioma; motor outcome; nTMS; navigated transcranial magnetic stimulation

Mesh:

Year:  2021        PMID: 34534966     DOI: 10.3171/2021.3.JNS2138

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  3 in total

1.  MRI-Based Risk Assessment for Incomplete Resection of Brain Metastases.

Authors:  Tizian Rosenstock; Paul Pöser; David Wasilewski; Hans-Christian Bauknecht; Ulrike Grittner; Thomas Picht; Martin Misch; Julia Sophie Onken; Peter Vajkoczy
Journal:  Front Oncol       Date:  2022-05-16       Impact factor: 5.738

2.  Surgery of Motor Eloquent Glioblastoma Guided by TMS-Informed Tractography: Driving Resection Completeness Towards Prolonged Survival.

Authors:  Carolin Weiss Lucas; Andrea Maria Faymonville; Ricardo Loução; Catharina Schroeter; Charlotte Nettekoven; Ana-Maria Oros-Peusquens; Karl Josef Langen; N Jon Shah; Gabriele Stoffels; Volker Neuschmelting; Tobias Blau; Hannah Neuschmelting; Martin Hellmich; Martin Kocher; Christian Grefkes; Roland Goldbrunner
Journal:  Front Oncol       Date:  2022-05-27       Impact factor: 5.738

3.  Impaired phase synchronization of motor-evoked potentials reflects the degree of motor dysfunction in the lesioned human brain.

Authors:  Georgios Naros; Kathrin Machetanz; Maria Teresa Leao; Sophie Wang; Marcos Tatagiba; Alireza Gharabaghi
Journal:  Hum Brain Mapp       Date:  2022-02-24       Impact factor: 5.399

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.